Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | AB-1015 |
Trade Name | |
Synonyms | AB 1015|AB1015 |
Drug Descriptions |
AB-1015 is an integrated circuit T (ICT) cell therapy that comprises T cells engineered to express a priming receptor that binds to ALPG/P and induces expression of a chimeric antigen receptor (CAR) that targets mesothelin (MSLN), as well as shRNA that targets FAS and PTPN2, potentially resulting in increased killing of ALPG/P and MSLN-expressing tumor cells (Cancer Res (2022) 82 (12_Supplement): 585). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C190955 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AB-1015 | AB-1015 | 0 | 1 |